Stay Ahead With Leasing Options for the Latest Sartorius Platforms

Unlock advanced bioprocessing technologies without the heavy upfront investment. Leasing Sartorius platforms like the KSep® system, Virus Counter® platform, and StreamLink® CC15 gives you financial flexibility, predictable costs, and the freedom to upgrade as your needs evolve. Stay current, cut risk, and keep your workflows moving forward.

  • Faster access to innovation: Start using the device immediately without waiting for budget approvals
  • Project-fit investment: Ideal for short-term programs (2-3 years), no need to commit capital
  • Flexible budgeting: Predictable monthly payments allow OPEX allocation instead of CAPEX
  • Stay ahead with upgrades: Option to upgrade the equipment at the end of the leasing period
  • Scalable solution: Add additional systems only when projects scale, without tying up budget long-term

Request Your Leasing Offer

Available Platforms

Ksep® Centrifuge Systems

StreamLink® CC 15​ Sample Preparation

Virus Counter® Platform

icon-directions
LeaseOwnership
Preserves cash – payments fall under OPEX for predictable budgeting Ties up capital that could be used for R&D, trials, or hiring 
Perfect for short-term programs – return the system when the project ends Inefficient if project runs only 1-2 years – risk of idle equipment afterwards 
Leasing available immediately – get started today, shorten time-to-market CAPEX approval can delay project start by months 

Consult Our Experts

Request Your Leasing Offer Today

FAQs

Yes. At the end and during your lease term you can refresh or upgrade to the latest features, such as new reagent kits or GMP-ready software modules, without being stuck with outdated equipment.

Absolutely. Preventive maintenance, remote support, and user training can be part of the package, keeping your team productive and your system running at full performance. 

By bundling service and consumables into the lease, you get a transparent and predictable cost per analysis. This makes it easier to compare against alternative assays like qPCR or ELISA.

Yes. Leasing is particularly attractive for grant-based projects since it aligns the instrument costs with the project duration and avoids post-grant budget gaps.

Leasing gives you immediate access to the technology without a heavy upfront investment. It turns the instrument into an operating expense, preserves your cash for R&D, and ensures flexibility if your project only runs for 1–2 years.